Content Analysis of FDA Warning Letters to Manufacturers of Pharmaceuticals and Therapeutic Biologicals for Promotional Violations

Abstract

Manufacturers of pharmaceuticals use advertising and promotion as key marketing activities to foster the success of their products. These activities, however, have to comply with FDA regulations; failure to do so results in FDA enforcement actions such as issuance of warning letters and notices of violation. The purpose of this study is to critically evaluate the content of FDA letters to manufacturers for promotional violations. Two judges formally trained in content analysis procedures critically evaluated the content of publicly available letters from 2000 to 2006. A total of 249 letters described 806 violations from 107 manufacturers. Media most frequently cited in letters were print (n −67), sales aids (n = 42), and television (n = 39). Violations were most frequently related to lack of fair balance (n = 131), misleading claims of efficacy (n = 102), misleading superiority claims (n = 92), and omission of risk information (n = 89). Inter-rater reliabilities between the two judges were exceptional, ranging from 0.89 to 1.00. The marketing of prescription drugs has a significant impact on the medication use process. Managed care policymakers and pharmacists should remain abreast of promotional strategies and claims, particularly those deemed problematic by the FDA, which may spur requests for additional information, prescriptions, or formulary status changes for the drugs promoted.

Keywords

FDA Warning letter Letter of notice Violations Drug promotional claims Content analysis

Get full access to this article

View all access options for this article.

References

Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising, and Communications.

Laws, regulations, guidances, and enforcement actions. Rockville, MD: US FDA. Available from: http://www.fda.gov/cder/ddmac/lawsregs.htm. Accessed March 10, 2007.

Bramstedt

. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration. Clin Invest Med. 2004; 27(6):316–323.

Bramstedt

Kassimatis

. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration. Clin Invest Med. 2004; 27(3):129–134.

Stewart

Neumann

. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: An analysis of warning letters and notices of violation. Value Health. 2002; 5(5):390–397.

Krippendorf

Klaus

. Content Analysis: An Introduction to Its Methodology. 2nd ed. Thousand Oaks, CA: Sage; 2004.

FDA Warning Letters. Available from: http://www.fda.gov/foi/warning.htm. Accessed March 10, 2007.

McGinn

Wyer

Newman

Keitz

Leipzig

Guyatt

. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). Can Med Assoc J. 2004; 171: 1369–1373.

Portnoy

. Advertising and promotion of medical devices. J Health Law. 2006; 29(2):265–282.

Kaeding

. It's in the mail—responding to an FDA warning letter. Wisconsin Technology Network. Available at: http://wistechnology.com/article.php?id=2117. Accessed October 5, 2007.

10.

Mitka

. Report criticizes lack of FDA oversight. JAMA. 2006; 296: 920–922.

11.

Benson

Alfors

. Prescription drug advertising and promotion: Learnings from recent Food and Drug Administration warning letters. Drug Inf J. 2007; 41: 281–289.

12.

Dickinson

. “Flip the ad” to see proper risk balance, says FDA. Medical Marketing and Media, September 1, 2007.

13.

Brown

. Fair balance: Legal hassle or competitive edge? DTC Perspectives Magazine. 2004; 3(2): 34–36.

14.

Holmes

Desselle

. Evaluating the balance of informative and persuasive content within product-specific print DTCs ads. Drug Inf J. 2004; 38: 83–98.

15.

Glinert

. TV commercials for prescription drugs: A discourse analytic perspective. Res Soc Adm Pharm. 2005; 1: 158–184.

16.

Radensky

. Outcomes research: When can the results be communicated? Drug Benefit Trends. 2000; 12(12):49–51.

17.

Neumann

Claxton

Weinstein

. The FDA's regulation of health economic information: How the Food and Drug Administration could improve the flow of economic information without discouraging research or exposing consumers to risk. Health Aff. 2000; 19(5):129–137.